


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
APPROVAL FOR MARKETING OF “GADOTERIDOL INJECTION”

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announced that the “Gadoteridol Injection” (trade name: Daxian (大顯)), a medical imaging product developed by the Group, has received the approval for marketing from the National Medical Products Administration of China.

Gadoteridol is a non-ionic magnetic resonance imaging (MRI) contrast agent for the examination of magnetic resonance (MR) enhancement scans applicable to the brain, spine and peripheral tissues lesions, as well as whole-body MRI examinations including examination for the head, neck, liver, mammary glands, musculoskeletal system, and soft tissue lesions.

Accompanied by the in-depth promotion of universal health coverage and wide application of medical imaging technology, the demand for contrast agents in China is high, and contrast agents have a broad application prospect. In 2022, the scale of China’s contrast agents market amounted to over RMB10 billion.

Daxian is consistent with the reference listed drug and will provide more options for the use of MRI contrast agents in clinical medical imaging in China. In addition to Daxian, the Group also has other approved contrast agent products such as gadoxetic acid disodium (trade name: Xianai (顯愛)) and iodixanol (trade name: Shabeian (沙貝安)), which together will form an advantageous product cluster in the field of diagnostic imaging for the benefit of more patients.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 12 June 2024

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.